101 related articles for article (PubMed ID: 30058268)
1. Long-term cost-effectiveness of a Patient Empowerment Programme for type 2 diabetes mellitus in primary care.
Lian J; McGhee SM; So C; Chau J; Wong CKH; Wong WCW; Lam CLK
Diabetes Obes Metab; 2019 Jan; 21(1):73-83. PubMed ID: 30058268
[TBL] [Abstract][Full Text] [Related]
2. Five-year cost-effectiveness of the Patient Empowerment Programme (PEP) for type 2 diabetes mellitus in primary care.
Lian J; McGhee SM; So C; Chau J; Wong CKH; Wong WCW; Lam CLK
Diabetes Obes Metab; 2017 Sep; 19(9):1312-1316. PubMed ID: 28230312
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Cost-effectiveness of the Multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM).
Jiao FF; Fung CSC; Wan EYF; Chan AKC; McGhee SM; Kwok RLP; Lam CLK
Diabetes Care; 2018 Feb; 41(2):250-257. PubMed ID: 29246949
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime.
Jiao F; Wan EYF; Fung CSC; Chan AKC; McGhee SM; Kwok RLP; Lam CLK
Endocrine; 2019 Feb; 63(2):259-269. PubMed ID: 30155847
[TBL] [Abstract][Full Text] [Related]
5. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.
Gillett M; Dallosso HM; Dixon S; Brennan A; Carey ME; Campbell MJ; Heller S; Khunti K; Skinner TC; Davies MJ
BMJ; 2010 Aug; 341():c4093. PubMed ID: 20729270
[TBL] [Abstract][Full Text] [Related]
6. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of patient-reported outcomes data in structured diabetes education intervention: 2-year follow-up data of patient empowerment programme.
Wong CK; Lam CL; Wan EY; Chan AK; Pak CH; Chan FW; Wong WC
Endocrine; 2016 Nov; 54(2):422-432. PubMed ID: 27623970
[TBL] [Abstract][Full Text] [Related]
10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis for a tele-based health coaching program for chronic disease in primary care.
Oksman E; Linna M; Hörhammer I; Lammintakanen J; Talja M
BMC Health Serv Res; 2017 Feb; 17(1):138. PubMed ID: 28202032
[TBL] [Abstract][Full Text] [Related]
12. Modelling the cost-effectiveness of pay-for-performance in primary care in the UK.
Pandya A; Doran T; Zhu J; Walker S; Arntson E; Ryan AM
BMC Med; 2018 Aug; 16(1):135. PubMed ID: 30153827
[TBL] [Abstract][Full Text] [Related]
13. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of a multicomponent quality improvement care model for diabetes in South Asia: The CARRS randomized clinical trial.
Singh K; Kondal D; Menon VU; Varthakavi PK; Viswanathan V; Dharmalingam M; Bantwal G; Sahay RK; Masood MQ; Khadgawat R; Desai A; Prabhakaran D; Narayan KMV; Phillips VL; Tandon N; Ali MK
Diabet Med; 2023 Sep; 40(9):e15074. PubMed ID: 36815284
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
16. A systematic review and economic evaluation of exercise referral schemes in primary care: a short report.
Campbell F; Holmes M; Everson-Hock E; Davis S; Buckley Woods H; Anokye N; Tappenden P; Kaltenthaler E
Health Technol Assess; 2015 Jul; 19(60):1-110. PubMed ID: 26222987
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
Tunis SL
Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
